Glioblastoma Response Prediction to Apatinib

Beijing Sanbo Brain Hospital

Status: Completed

Conditions: Glioblastoma

Treatments: Other: genetic characteristic

Study type: Observational

Funder types: Other

Identifiers

NCT04814329

2021ZZLX03

Details and patient eligibility

About

Anti-angiogenic therapy is an important treatment strategy for recurrent glioblastoma. Our previous study provided evidence for a potential benefit of apatinib, a humanized monoclonal antibody against VEGFR-2, when added to temozolomide chemotherapy in patients with recurrent glioblastoma. Some patients showed durable responses and prolonged survival, with recorded survival times of over 30 months in 6.4% patients. However, a subset of patients progressed in 2 months. There is a strong need to better predict and monitor apatinib treatment response to prevent patients from adverse effects of ineffective therapy. In this study, whole genome sequencing and RNA-sequencing of formalin-fixed, paraffin-embedded tumor materials from the participants who received apatinib and temozolomide treatment will be performed to identify the response biomarkers and patients who may benefit most from apatinib, avoiding unnecessary potential toxicity and cost for those who are unlikely to benefit from the drug.

Enrollment: 18 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-70 years old
2. recurrent glioblastoma
3. received apatinib plus temozolomide treatment，response and survival data were available
4. tumor tissues were acquired

Exclusion criteria

Trial design

18 participants in 3 patient groups

effective group

Description:

After treatment, tumor achieved complete response or partial response and the progression-free survival time was ≥6 months.

Treatment:

Other: genetic characteristic

stable group

Description:

After treatment, tumor remains stable and the progression-free survival time was more than 1 month and less than 6 months.

Treatment:

Other: genetic characteristic

Early progressed group

Description:

After treatment, tumor got progressed and the progression-free survival time was no more than 1 month.

Treatment:

Other: genetic characteristic